Maurice Chagnaud

Dr. Maurice Chagnaud has over 22 years experience as a senior executive in the healthcare and pharmaceutical industry with a broad range of regional, functional, and general management experience. He was most recently the CEO of Polpharma, which is one of the largest pharma companies based in Eastern Europe with over $1 billion in sales. Prior to this role, he was the President for Europe and Global Head of Inhalation Product Strategy for Lupin. Dr. Chagnaud was with Teva Group for over 8 years in a variety roles that included being President of the CEE region, one of the largest regions for Teva, and Chief Commercial Officer for Europe, where he led the integration of several acquisitions in the five largest country markets. He was with Merck Generics (Merck Group) for 12 years, as General Manager in France and Italy. He is an expert on different go-to market strategies for generics and the OTC market. He also has an extensive background in the respiratory market, specialities, B2B market, and a pioneer in the biosimilars market in Europe. His experience includes large-scale transformation and growth through M&A. Dr. Chagnaud received his medical degree from the University La Timone and practiced medicine for 4 years before switching to industry. He has an MBA from IAE Aix-Marseille.